Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SELB

Selecta Biosciences (SELB) Stock Price, News & Analysis

Selecta Biosciences logo

About Selecta Biosciences Stock (NASDAQ:SELB)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.88
$1.26
52-Week Range
N/A
Volume
2.77 million shs
Average Volume
979,585 shs
Market Capitalization
$136.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Selecta Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
22nd Percentile Overall Score

SELB MarketRank™: 

Selecta Biosciences scored higher than 22% of companies evaluated by MarketBeat, and ranked 831st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Selecta Biosciences.

  • Earnings Growth

    Earnings for Selecta Biosciences are expected to grow in the coming year, from ($0.33) to ($0.07) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Selecta Biosciences is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Selecta Biosciences is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for SELB.
  • Dividend Yield

    Selecta Biosciences does not currently pay a dividend.

  • Dividend Growth

    Selecta Biosciences does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for SELB.
  • Search Interest

    1 people have searched for SELB on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Selecta Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    31.20% of the stock of Selecta Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    41.95% of the stock of Selecta Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Selecta Biosciences' insider trading history.
Receive SELB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SELB Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Cartesian Therapeutics Inc (RNAC)
See More Headlines

SELB Stock Analysis - Frequently Asked Questions

Selecta Biosciences, Inc. (NASDAQ:SELB) released its quarterly earnings data on Thursday, August, 17th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.05. The firm had revenue of $5.25 million for the quarter, compared to analyst estimates of $9.90 million. Selecta Biosciences had a negative net margin of 72.04% and a negative trailing twelve-month return on equity of 44.13%.
Read the conference call transcript
.

Selecta Biosciences (SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Selecta Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), GE Aerospace (GE), Pfizer (PFE), CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/17/2023
Today
8/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:SELB
CIK
1453687
Employees
64
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.22)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$35.38 million
Net Margins
-72.04%
Pretax Margin
-73.23%
Return on Equity
-44.13%
Return on Assets
-22.00%

Debt

Debt-to-Equity Ratio
0.21
Current Ratio
4.18
Quick Ratio
4.18

Sales & Book Value

Annual Sales
$110.78 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
9.91
Book Value
$0.61 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
155,200,000
Free Float
106,780,000
Market Cap
$136.76 million
Optionable
Optionable
Beta
0.84

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:SELB) was last updated on 8/3/2025 by MarketBeat.com Staff
From Our Partners